Message
From the Board Chair & Executive Director
The arrival of COVID-19 has brought profound and often tragic disruptions to every facet of life.
In 2021, we have nonetheless witnessed more of the astounding achievements that can be made through global investment into the research and development of diagnostics, vaccines, and treatments. We have also realised that, in the absence of equitable access to these tools, the SARS-CoV-2 virus continues to propagate and mutate, rendering all of us vulnerable.
The issue of inequitable access to new health technologies to address COVID-19 has highlighted the importance of our mission to accelerate the development and access of treatments for drug-resistant infections. A recent study in The Lancet highlighted the nearly 1.3 million deaths that occurred in 2019 due to antimicrobial resistance—more than malaria and HIV/AIDS—and made the case for greater access to effective antibiotics for all people. The importance of GARDP’s mission could not be more evident.
2021 progress
Children’s Antibiotics
IDENTIFIED
three potential combination treatments for neonatal sepsis
ADVANCED
the clinical development of cefepime-taniborbactam for children
INITIATED
collaborations to develop access to antibiotics
Sexually transmitted infections
ADVANCed r&D
through several projects, including the development of an in vitro Hollow Fibre Infection Model (HFIM) to examine the pharmacodynamic dosing, bacterial kill, and resistance suppression of zoliflodacin against Neisseria gonorrhoeae
ACTIVATED
new countries and sites and recovered recruitment (following the impact of the COVID-19 pandemic) for the phase 3 trial of zoliflodacin, a potential treatment for gonorrhoea
led
key initiatives that will facilitate future access to zoliflodacin
Serious bacterial infections
COMPLETED
Venatorx enrolment for the pivotal phase 3 trial of cefepime–taniborbactam, a promising new antibiotic treatment
identifiED
sites to be part of a network in India and South Africa that will improve our understanding of how to treat drug-resistant infections in adults and children
initiated
an agreement to deliver access to cefiderocol in the countries that need it most
Advancing antibiotic R&D
SCREENING
chemical compound libraries in search of potential new antibiotics with activity against drug-resistant pathogens that urgently require new treatments
DEVELOPING
GARDP’s models and
collaborations to enable the
identification of hit compounds and their prioritization for further work
IDENTIFYING
gaps in the global DER ecosystem to facilitate the exploration of opportunities for developing new discovery projects
deliver access for all
Deliver Access for All
Help us fight antibiotic resistance
